SGMO Sangamo Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SGMO

Price (delayed)

$0.5438

Market cap

$97.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$84.1M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
SGMO's debt is down by 14% YoY and by 4.2% QoQ
The revenue has soared by 58% year-on-year but it is down by 13% since the previous quarter
The gross profit has soared by 58% YoY but it fell by 13% QoQ
The equity has shrunk by 72% YoY and by 39% QoQ
The quick ratio has declined by 37% since the previous quarter and by 31% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sangamo.com
Peers: ALNY GILD AMGN BIIB

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
178.91M
Market cap
$97.29M
Enterprise value
$84.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
0.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.48
Earnings
Revenue
$176.23M
EBIT
-$262.9M
EBITDA
-$240.71M
Free cash flow
-$246M
Per share
EPS
-$1.48
Free cash flow per share
-$1.41
Book value per share
$0.47
Revenue per share
$1.01
TBVPS
$0.95
Balance sheet
Total assets
$165.32M
Total liabilities
$82.43M
Debt
$33.52M
Equity
$82.89M
Working capital
$46.6M
Liquidity
Debt to equity
0.4
Current ratio
1.98
Quick ratio
1.75
Net debt/EBITDA
0.05
Margins
EBITDA margin
-136.6%
Gross margin
100%
Net margin
-146.3%
Operating margin
-155.5%
Efficiency
Return on assets
-89.6%
Return on equity
-131%
Return on invested capital
-134.6%
Return on capital employed
-223.6%
Return on sales
-149.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
6.63%
1 week
10.98%
1 month
-10.5%
1 year
-63.99%
YTD
0.09%
QTD
-18.86%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$176.23M
Gross profit
$176.23M
Operating income
-$274.01M
Net income
-$257.83M
Gross margin
100%
Net margin
-146.3%
The revenue has soared by 58% year-on-year but it is down by 13% since the previous quarter
The gross profit has soared by 58% YoY but it fell by 13% QoQ
The operating income has contracted by 36% YoY and by 2.5% from the previous quarter
Sangamo Therapeutics's net income has decreased by 34% YoY and by 3.3% QoQ

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
1.16
P/S
0.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.48
The EPS has declined by 18% year-on-year and by 2.8% since the previous quarter
The equity has shrunk by 72% YoY and by 39% QoQ
The price to book (P/B) is 54% lower than the 5-year quarterly average of 2.4 but 22% higher than the last 4 quarters average of 0.9
The stock's P/S is 94% below its 5-year quarterly average of 8.4 and 36% below its last 4 quarters average of 0.8
The revenue has soared by 58% year-on-year but it is down by 13% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The company's return on assets has shrunk by 183% YoY and by 39% QoQ
Sangamo Therapeutics's return on invested capital has shrunk by 134% YoY and by 29% QoQ
The ROE has plunged by 114% YoY and by 31% from the previous quarter
The return on sales has declined by 18% since the previous quarter but it is up by 13% year-on-year

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 101% greater than its total liabilities
SGMO's total assets has dropped by 71% year-on-year and by 25% since the previous quarter
SGMO's total liabilities has dropped by 69% year-on-year and by 2.8% since the previous quarter
SGMO's debt is 60% lower than its equity
The equity has shrunk by 72% YoY and by 39% QoQ
Sangamo Therapeutics's debt to equity has surged by 54% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.